Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: QS stock price vs SUPN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SUPN's multiple
Needs Revenue / share.
Implied fair value · at QS's multiple
Needs QS P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: QS FY 2025 (ended Dec 31, 2025) · SUPN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / EBITDA 0.99x
Capital structure 98% equity / 2% debt · EV / Revenue 3.40x · EV / EBITDA 50.52x
SUPN carries the larger enterprise value at $2.45B against -$425.39M; QS trades on the lower EV / EBITDA multiple (0.99x vs 50.52x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
QUANTUMSCAPE CORPORATION · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.02x
0.04x
Net debt / EBITDA
Leverage against operating earnings
2.21x
-1.75x
Cash and equivalents
Liquid reserves on the balance sheet
$970.81M
$128.45M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Microvast Holdings, Inc.
QS vs MVST
Fluence Energy, Inc.
QS vs FLNC
Enovix Corp
QS vs ENVX
APPLIED MATERIALS INC /DE
QS vs AMAT
Jazz Pharmaceuticals plc
QS vs JAZZ
INCYTE CORP
QS vs INCY
ANI PHARMACEUTICALS INC
QS vs ANIP
Vanda Pharmaceuticals Inc.
QS vs VNDA
Harmony Biosciences Holdings, Inc.
QS vs HRMY
$22.36M
$43.80M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
